Reporting segmentation of the pharmacy business
First written in FY2022-Q1. 1 of 14 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Interim pharmacy business performance: higher revenue and profitAnnual report
「In the pharmacy business, sales increased despite a decline in the number of prescriptions received, due in part to efforts to increase revenue from dispensing technical fees and pharmaceutical management fees. Profit also increased as a result of efforts to qualify for dispensing fees related to primary pharmacy functions and to manage costs. As a result, sales amounted to ¥9,870 million, or 101.5% of the year-earlier period, and segment profit (operating profit) was ¥135 million, or 141.3% of the year-earlier period.」
The interim results have been updated, showing higher revenue and profit due to increases in dispensing technical fees and pharmaceutical management fees, qualification for dispensing fees, and cost management despite a decline in prescription volume. - FY2025Updated full-year pharmacy business resultsAnnual report
「Sales to external customers amounted to ¥19,552 million, compared with ¥19,115 million in the previous fiscal year, while segment profit was ¥251 million, compared with ¥310 million in the previous fiscal year.」
The FY2025 full-year results for the pharmacy business, which is a separate reportable segment, have been updated. - FY2025-H1Interim pharmacy business performance: higher revenue, lower profitAnnual report
「In the pharmacy business, although the number of prescriptions received declined, revenue increased as a result of efforts including expanding dispensing fee revenue and medication management fee revenue. Profit declined, however, due to the impact of drug price revisions and longer prescription periods. As a result, revenue was ¥9,725 million, or 103.6% of the previous interim consolidated accounting period, and segment profit (operating profit) was ¥96 million, or 83.7% of the previous interim consolidated accounting period.」
For the pharmacy business, presented as a separate reportable segment, interim sales of ¥9,725 million and segment profit of ¥96 million have been disclosed. - FY2024Full-year pharmacy operations results; profit growthAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition in August 2023. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue from external customers was ¥19,115 million, compared with ¥18,361 million in the previous fiscal year, and segment profit increased to ¥310 million, compared with ¥106 million in the previous fiscal year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
For the pharmacy business, presented as a separate reportable segment, FY2024 full-year sales of ¥19,115 million and segment profit of ¥310 million have been updated. - FY2024-Q3Third-quarter pharmacy operations results; profit growthAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition in August 2023. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥14,295 million, compared with ¥13,769 million in the same period of the previous year. Segment profit (operating profit) increased to ¥259 million, compared with ¥77 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The cumulative third-quarter sales and segment profit for the pharmacy business, presented as a separate reportable segment, have been updated. - FY2024-Q2Second-quarter pharmacy business results, profit increaseAnnual report
「In pharmacy operations, the number of stores increased by 1 through a business acquisition. In addition, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue, while the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥9,386 million, compared with ¥9,009 million in the same period of the previous year. Segment profit (operating profit) increased to ¥114 million, compared with ¥32 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The cumulative second-quarter results for the pharmacy business, presented as a separate reportable segment, have been updated. Both sales and segment profit exceeded the year-earlier period. - FY2024-Q1First-quarter segment results, profit increaseAnnual report
「In pharmacy operations, efforts were made to increase dispensing technical fee revenue and pharmaceutical management fee revenue. In addition, the number of prescriptions received increased due to higher foot traffic following the reclassification of COVID-19 under the Infectious Diseases Control Law to Category 5, among other factors. As a result, revenue was ¥4,654 million, compared with ¥4,481 million in the same period of the previous year. Segment profit (operating profit) increased to ¥87 million, compared with ¥14 million in the same period of the previous year, due to the effect of higher revenue and a substantial decline in amortization of goodwill.」
The pharmacy business recorded higher revenue and profit due to increases in dispensing technical fees and pharmaceutical management fees, an increase in prescription volume resulting from greater foot traffic after the transition to Category 5, and lower amortization of goodwill. - FY2023Updated full-year pharmacy business resultsAnnual report
「In pharmacy operations, efforts were made to calculate the relevant dispensing fees with the aim of becoming the family pharmacy sought by the government. However, due to the impact of the drug price revision, revenue from external customers was ¥18,361 million, down 0.2% from the previous consolidated fiscal year, and segment profit was ¥106 million, down 48.1%.」
The pharmacy business continues to be disclosed as a separate reportable segment, and its full-year results have been updated. - FY2023-Q3Third-quarter pharmacy business results, profit declineAnnual report
「In the pharmacy business, the company worked to qualify for relevant dispensing fees with the aim of becoming a primary pharmacy as sought by the government. However, due to the impact of the drug price revision, sales amounted to ¥13,769 million, or 99.8% of the year-earlier period, and segment profit (operating profit) was ¥77 million, or 47.7% of the year-earlier period.」
The pharmacy business advanced initiatives to become a primary pharmacy, while revenue and profit declined due to the impact of the drug price revision. - FY2023-Q2Second-quarter segment results, profit declineAnnual report
「In the pharmacy business, the company worked to qualify for relevant dispensing fees with the aim of becoming a primary pharmacy as sought by the government. However, due to the impact of the drug price revision, sales amounted to ¥9,009 million, or 99.6% of the year-earlier period, and segment profit (operating profit) was ¥32 million, or 39.6% of the year-earlier period.」
The cumulative second-quarter results for the pharmacy business in FY2023 have been updated. Revenue and profit declined due to the impact of the drug price revision, despite efforts to develop primary pharmacy services. - FY2023-Q1Updated first-quarter segment results, profit declineAnnual report
「In the pharmacy business, efforts to strengthen pharmacy functions with the aim of becoming a community-based primary pharmacy resulted in sales of ¥4,481 million, or 101.0% of the year-earlier period. Segment profit (operating profit), however, was ¥14 million, or 36.5% of the year-earlier period, due to the impact of the negative revision to official drug prices.」
The pharmacy business recorded higher revenue, while segment profit declined to 36.5% of the year-earlier period due to the impact of the negative revision to official drug prices. - FY2022AchievedAnnual report
「Beginning with the current fiscal year, the method of classifying business segments has been revised for the pharmacy business, which was previously included in Other, and the business is now presented as a reportable segment.」
The pharmacy business has been presented as a separate reportable segment rather than under Other in the full-year disclosure. - FY2022-Q3RestatedAnnual report
「In the first quarter of the consolidated fiscal year, the classification of reporting segments was changed.」
The change in the classification of reportable segments from the first quarter has been reconfirmed. - FY2022-Q1First statedAnnual report
「Beginning with the cumulative first-quarter period of the current fiscal year, the method of classifying business segments has been revised for the pharmacy business, which was previously included in Other, and the business is now presented as a reportable segment.」
The pharmacy business, previously included in Other, has been presented separately as a reportable segment beginning with the cumulative first-quarter period of the current fiscal year.